Novel Therapies of Salivary Gland Cancer

Dear Colleagues,

Salivary gland cancer presents significant challenges due to its diverse histological subtypes; variable clinical behavior; and, like other head-and neck cancer subtypes, limited treatment options. Despite advancements in surgery, radiation therapy, and chemotherapy, the prognosis for patients with advanced or recurrent disease remains poor, highlighting the urgent need for novel therapeutic approaches.

Advances in molecular biology, immunology, and targeted therapies enable new therapeutic goals. These novel approaches aim to improve outcomes by enhancing tumor specificity, minimizing systemic toxicity, and overcoming treatment resistance. Additionally, a deeper understanding of the molecular pathways involved in salivary gland tumorigenesis has provided new opportunities for targeted intervention, paving the way for personalized treatment approaches tailored to the unique characteristics of individual tumors.

This Special Issue aims to support publishing manuscripts which provide emerging therapies for salivary gland cancer, encompassing both conventional modalities and cutting-edge advancements in the field. By elucidating the current landscape of therapeutic options and highlighting promising avenues for future research, this Special Issue seeks to contribute to the ongoing efforts made to improve outcomes and quality of life for patients with salivary gland cancer.

Dr. Moritz Meyer
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• salivary gland cancer
• treatment
• targeted therapy
• surgery
• radiation therapy
• survival
• life quality
• immunotherapy